Business
MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Initiated VALUE, a global Phase III pivotal trial of EscharEx® for venous leg ulcers Expanded strategic research collaborations with industry leaders, now including Kerecis $20 million in revenue for 2024; $24 million projected for 2025; $44 million in cash as of Year-End 2024 Conference call today, March 19 at 8:30am Eastern Time YAVNE, Israel, March 19, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today ann
About this update from Mediwound Ltd.
[{"type":"image","alt":"MediWound Ltd.","displaySize":"","headline":null,"caption":"MediWound Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":113,"url":"https://media.zenfs.com/en/globenewswire.com/ad5b557425c9c98b1d6e3e31c57b3159"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/lMBSATvDCuA9PnawJVvewQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ad5b557425c9c98b1d6e3e31c57b3159","width":300,"height":113}},"lazy":false},{"type":"text","content":"Initiated VALUE, a global Phase III pivotal trial of EscharEx® for venous leg ulcers","length":84,"tagName":"p"},{"type":"text","content":"Expanded strategic research collaborations with industry leaders, now including Kerecis $20 million in revenue for 2024; $24 million projected for 2025; $44 million in cash as of Year-End 2024","length":193,"tagName":"p"},{"type":"text","content":"Conference call today, March 19 at 8:30am Eastern Time","length":54,"tagName":"p"},{"type":"text","content":"YAVNE, Israel, March 19, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided a corporate update.","length":286,"tagName":"p"},{"type":"text","content":"“2024 was a pivotal year for MediWound, marked by strong execution, clinical progress, and strategic collaborations,” said Ofer Gonen, CEO of MediWound. “The initiation of the VALUE Phase III pivotal study is another major milestone, further reinforced by partnerships with industry leaders that highlight EscharEx’s clinical and commercial potential. At the same time, the global adoption of NexoBrid continues to accelerate, solidifying its critical role in modern burn care. With our innovative therapies advancing in wound and burn management and a solid financial foundation, we enter 2025 with momentum and a clear vision to drive meaningful impact for patients worldwide.”","length":679,"tagName":"p"},{"type":"text","content":"2024 Highlights and Recent Developments:","length":40,"tagName":"p"},{"type":"text","content":"EscharEx® ","length":9,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Initiated VALUE, a global pivotal Phase III trial to evaluate EscharEx for...